Reproductive Techniques, AssistedOvoVidNCT05473039
Effect of a Multivitamin Supplement With Probiotic (Seidivid Ferty4®) on Oocyte Retrieval and Quality
A study testing Seidivid Ferty4 in people with Reproductive Techniques, Assisted, run by SEID S.A. at 1 site in Spain.
Trial summary
This study evaluates the effect of pretreatment with a multivitamin supplement with probiotics (Seidivid Ferty4®) on oocyte retrieval in normo-responder patients undergoing controlled ovarian hyperstimulation (COH) for oocyte donation, considering both the total number of oocytes retrieved and the number of mature… Read more about this study
- Who is it for?
- Ages 18 to 34 years, women only
- Conditions the study is for
- Reproductive Techniques, Assisted
- What is being tested?
- Seidivid Ferty4
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 196 participants
- Where
- 1 siteSpain
- Study dates
- 11 Jul 2022to 28 Dec 2024
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 34 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Women undergoing COH for egg donation cycles
- Signing of Informed Consent
- Age 18-34 years
- Body mass index between 18-29.9 kg/m2
- Meet the criteria for inclusion in the oocyte donation program of the Next Fertility center
- Ultrasound antral follicle count before COH of ≥15 follicles
Who cannot join
- Patients excluded from the oocyte donation program
- Untreated sexually transmitted disease, HIV, HCV, HBV positive serology
- Blood disorders, neurodegenerative/psychiatric diseases, fragile X syndrome, oncological diseases, endometriosis.
- Polycystic ovary syndrome
- Oligomenorrhea (<1 menstrual cycle in 3 months)
- Diabetic patients
Trial locations and contacts
1 site in 1 country.
About this study
Official title: OvoVid Study: Effect of a Multivitamin Supplement With Probiotic (Seidivid Ferty4®) on Oocyte Retrieval and Quality in Oocyte Donors. Double-blind Randomized Placebo-controlled Clinical Trial
This study evaluates the effect of pretreatment with a multivitamin supplement with probiotics (Seidivid Ferty4®) on oocyte retrieval in normo-responder patients undergoing controlled ovarian hyperstimulation (COH) for oocyte donation, considering both the total number of oocytes retrieved and the number of mature oocytes retrieved, that is, in metaphase II (MII).
Read the detailed description
Patients will be recruited on the day they are going to start the egg donation program. The patient will start taking the study treatment (multivitamin supplement with probiotics or placebo) immediately after inclusion and will call the site to initiate the oocyte donation protocol approximately 30 days after enrollment. Throughout the COH period of the protocol the patient will continue taking the study supplement (or placebo), without interruption until the day of the GnRH-agonist trigger. The administration of the agonist will be as a single dose, 36 hours before follicular puncture for the retrieval of mature eggs. Then, the retrieved oocytes will be denuded and examined by light microscopy to assess their quality. The evaluation will carried out by two different embryologists, blinded to the study protocol.
- Conditions
- Reproductive Techniques, Assisted
- Being tested
- Seidivid Ferty4, Placebo
- Keywords
- oocyte maduration, oocyte donation, dietary supplement
- Medical subject headings
- Helping Behavior
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Seidivid Ferty4Dietary supplement
The patient will start taking the study treatment (multivitamin supplement with probiotics) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the diatary supplement, without interruption until the day of the GnRH-agonist trigger.
PlaceboOther
The patient will start taking the study treatment (placebo) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the treatment (placebo), without interruption until the day of the GnRH-agonist trigger.
| Study group | Role | What they receive |
|---|---|---|
| Seidivid Ferty4 | Experimental | Patients included in this group will be administered dietary supplement Seidivid Ferty4 (2 capsules per day, as a single dose) for at least 30 days prior to controlled ovarian hyperstimulation and until the day of the agonist trigger (GnRH a). Receives: Dietary Supplement: Seidivid Ferty4 |
| Placebo | Placebo comparator | Patients included in this group will be administered placebo (2 capsules per day, as a single dose) for at least 30 days prior to controlled ovarian hyperstimulation and until the day of the agonist trigger (GnRH-a). Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Oocytes Retrieved
Total number of oocytes retrieved in the follicular puncture
Measured: Through study completion, an average of 42 days
Number of Mature (MII) Oocytes Retrieved
Total number of mature oocytes (metaphase II, or MII) retrieved in the follicular puncture
Measured: Through study completion, an average of 42 days
Secondary outcomes (8)
Number of Good Quality Oocytes
Number of oocytes MII without dimorphisms
Measured: Through study completion, an average of 42 days
Number of Oocytes With Dimorphisms
Number of mature oocytes MII with dimorphisms
Measured: Through study completion, an average of 42 days
Number of Follicles at the Time of Trigger Administration
Ultrasound follicle count at the time of trigger administration
Measured: Through trigger administration, an average of 40 days
Fasting Glucose After 30 Days of Treatment With Dietary Supplement.
Fasting blood glucose at the start of controlled ovarian hyperstimulation (COH)
Measured: Through COH start, an average of 30 days
AST After 30 Days of Treatment With Dietary Supplement.
Serum aspartate aminotransferase (AST) levels at the time of controlled ovarian hyperstimulation (COH) start
Measured: Through COH start, an average of 30 days
ALT After 30 Days of Treatment With Dietary Supplement.
Serum alanine aminotransferase (ALT) levels at the time of controlled ovarian hyperstimulation (COH) start
Measured: Through COH start, an average of 30 days
Cholesterol After 30 Days of Treatment With Dietary Supplement.
Total cholesterol at the time of controlled ovarian hyperstimulation (COH) start
Measured: Through COH start, an average of 30 days
LH at the Time of COH Start
Plasma levels of luteinizing hormone (LH) at the time of controlled ovarian hyperstimulation (COH) start
Measured: Through COH start, an average of 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jul 2022
- Study start11 Jul 2022
- Primary completion1 Jul 2024
- Study completion28 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Reproductive Techniques, AssistedStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This is a single-center, randomized, double-blind, placebo-controlled clinical trial with a dietary supplement with probiotics, with two parallel group of subjects. Based on previous studies, considering this study as a non-inferiority versus placebo study the calculated sample size of subjects is 210 (105 subject for each arm). Once the informed consent is signed, the patient will be assigned a patient code and will be given the treatment box (white and with no label) corresponding to her code. The patient will start taking the study treatment (multivitamin supplement with probiotics or placebo) immediately after inclusion. Throughout the COH period the patient will continue taking the study supplement and will undergo the regular ultrasound controls of the egg donation program for evolutive control of the number and growth of follicles, without interruption until the day of the GnRH-agonist trigger.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 196 participants (actual)
Sponsor and investigators
- Lead sponsor
- SEID S.A.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Luis Quintero, Ph, Study director, NextFertility Valencia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05473039
- Sponsor's protocol ID
- OVOVID-FERTY4-2022-01
- Acronym
- OvoVid
- Status last verified
- Jun 2025
- First submitted
- 27 Jun 2022
- Last updated
- 13 Aug 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: There is no plan to make IPD available because the voluntary participating oocyte donors are healthy women and are not amenable to further follow-up.
Publications
Bonta S, Maggi S, Rodriguez R, Jimenez R, Villaquiran AM, Pla E, Fuentes R, Luque MD, Ferrer J, Quintero L. Ovovid trial: the effect of a probiotic micronutrients supplement on oocyte retrieval and quality in oocyte donors. A double blind, randomized controlled trial. J Assist Reprod Genet. 2026 Feb;43(2):603-613. doi: 10.1007/s10815-025-03763-4. Epub 2025 Dec 9.
PubMed 41361728
Study at a glance
From the registry record, last updated by the sponsor on 13 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- OvoVid Study: Effect of a Multivitamin Supplement With Probiotic (Seidivid Ferty4®) on Oocyte Retrieval and Quality in Oocyte Donors. Double-blind Randomized Placebo-controlled Clinical Trial
- ClinicalTrials.gov ID
- NCT05473039
- Acronym / sponsor ID
- OvoVid / OVOVID-FERTY4-2022-01
- Conditions
- Reproductive Techniques, Assisted
- Keywords
- oocyte maduration, oocyte donation, dietary supplement
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 196 participants (actual)
- Lead sponsor
- SEID S.A.Industry (pharma, biotech, devices)
- Study start
- 11 Jul 2022 (actual)
- Primary completion
- 1 Jul 2024 (actual)
- Study completion
- 28 Dec 2024 (actual)
- First posted
- 25 Jul 2022 (actual)
- Results
- Posted 13 Aug 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates the effect of pretreatment with a multivitamin supplement with probiotics (Seidivid Ferty4®) on oocyte retrieval in normo-responder patients undergoing controlled ovarian hyperstimulation (COH) for oocyte donation, considering both the total number of oocytes retrieved and the number of mature oocytes retrieved, that is, in metaphase II (MII).
Detailed description
Patients will be recruited on the day they are going to start the egg donation program. The patient will start taking the study treatment (multivitamin supplement with probiotics or placebo) immediately after inclusion and will call the site to initiate the oocyte donation protocol approximately 30 days after enrollment. Throughout the COH period of the protocol the patient will continue taking the study supplement (or placebo), without interruption until the day of the GnRH-agonist trigger. The administration of the agonist will be as a single dose, 36 hours before follicular puncture for the retrieval of mature eggs. Then, the retrieved oocytes will be denuded and examined by light microscopy to assess their quality. The evaluation will carried out by two different embryologists, blinded to the study protocol.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- This is a single-center, randomized, double-blind, placebo-controlled clinical trial with a dietary supplement with probiotics, with two parallel group of subjects. Based on previous studies, considering this study as a non-inferiority versus placebo study the calculated sample size of subjects is 210 (105 subject for each arm). Once the informed consent is signed, the patient will be assigned a patient code and will be given the treatment box (white and with no label) corresponding to her code. The patient will start taking the study treatment (multivitamin supplement with probiotics or placebo) immediately after inclusion. Throughout the COH period the patient will continue taking the study supplement and will undergo the regular ultrasound controls of the egg donation program for evolutive control of the number and growth of follicles, without interruption until the day of the GnRH-agonist trigger.
| Arm | Type | Receives |
|---|---|---|
| Seidivid Ferty4 | Experimental | Dietary Supplement: Seidivid Ferty4Patients included in this group will be administered dietary supplement Seidivid Ferty4 (2 capsules per day, as a single dose) for at least 30 days prior to controlled ovarian hyperstimulation and until the day of the agonist trigger (GnRH a). |
| Placebo | Placebo comparator | Other: PlaceboPatients included in this group will be administered placebo (2 capsules per day, as a single dose) for at least 30 days prior to controlled ovarian hyperstimulation and until the day of the agonist trigger (GnRH-a). |
Who may qualify
- Ages
- 18 to 34 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Women undergoing COH for egg donation cycles
- Signing of Informed Consent
- Age 18-34 years
- Body mass index between 18-29.9 kg/m2
- Meet the criteria for inclusion in the oocyte donation program of the Next Fertility center
Key exclusion criteria (6 listed)
- Patients excluded from the oocyte donation program
- Untreated sexually transmitted disease, HIV, HCV, HBV positive serology
- Blood disorders, neurodegenerative/psychiatric diseases, fragile X syndrome, oncological diseases, endometriosis.
- Polycystic ovary syndrome
- Oligomenorrhea (<1 menstrual cycle in 3 months)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Seidivid Ferty4The patient will start taking the study treatment (multivitamin supplement with probiotics) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the diatary supplement, without interruption until the day of the GnRH-agonist trigger. | Dietary supplement | Seidivid Ferty4 |
| PlaceboThe patient will start taking the study treatment (placebo) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the treatment (placebo), without interruption until the day of the GnRH-agonist trigger. | Other | Placebo |
Primary outcome
Number of Oocytes Retrieved
Time frame: Through study completion, an average of 42 days
Total number of oocytes retrieved in the follicular puncture
Number of Mature (MII) Oocytes Retrieved
Time frame: Through study completion, an average of 42 days
Total number of mature oocytes (metaphase II, or MII) retrieved in the follicular puncture
8 secondary outcomes
Number of Good Quality Oocytes
Time frame: Through study completion, an average of 42 days
Number of Oocytes With Dimorphisms
Time frame: Through study completion, an average of 42 days
Number of Follicles at the Time of Trigger Administration
Time frame: Through trigger administration, an average of 40 days
Fasting Glucose After 30 Days of Treatment With Dietary Supplement.
Time frame: Through COH start, an average of 30 days
AST After 30 Days of Treatment With Dietary Supplement.
Time frame: Through COH start, an average of 30 days
ALT After 30 Days of Treatment With Dietary Supplement.
Time frame: Through COH start, an average of 30 days
Cholesterol After 30 Days of Treatment With Dietary Supplement.
Time frame: Through COH start, an average of 30 days
LH at the Time of COH Start
Time frame: Through COH start, an average of 30 days
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Aug 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 41361728Bonta S, Maggi S, Rodriguez R, Jimenez R, Villaquiran AM, Pla E, Fuentes R, Luque MD, Ferrer J, Quintero L. Ovovid trial: the effect of a probiotic micronutrients supplement on oocyte retrieval and quality in oocyte donors. A double blind, randomized controlled trial. J Assist Reprod Genet. 2026 Feb;43(2):603-613. doi: 10.1007/s10815-025-03763-4. Epub 2025 Dec 9.
- Individual participant dataSharing planned: No. There is no plan to make IPD available because the voluntary participating oocyte donors are healthy women and are not amenable to further follow-up.
Related trials for Reproductive Techniques, Assisted
Enrolling by invitation
A Web-Based Tool to Help People With Health Conditions Make Contraceptive Decisions
Contraceptive Usage, Contraceptive Behavior
Enrolling by invitation
Multifaceted Benefits of Auricular Point Sticking for IVF Patients: Psychological Well-being, Sleep, and Treatment Outcomes
Infertility, Female, Anxiety
Recruiting
The Feasibility of taVNS on Pregnancy Outcomes of Infertility Patients Undergoing IVF
Infertility Assisted Reproductive Technology
RecruitingObservational study
Food Intake Among Women and Men in Fertility Treatment
Infertility
RecruitingObservational study
Discarded Materials Study
Infertility
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Luis Quintero, Ph study director
NextFertility Valencia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Seidivid Ferty4 in people with Reproductive Techniques, Assisted, run by SEID S.A. at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 13 Aug 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Oocytes Retrieved (time frame: Through study completion, an average of 42 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05473039, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2025.